Ämnen: Haelso-sjukvaard

  • Sanofi-aventis affirms its commitment to Access to Medicines in the "Southern countries", with a policy of tiered drug prices geared to populations incomes

    Contact : Dr. Robert SEBBAG +33 (0)1 53 77 47 80 +33 (0)6 08 17 21 83 EMBARGO UNTIL APRIL 15, 2005 – 1:00 p.m. (CET) In his address to the closing plenary session of BioVision – the World Life Sciences Forum - Jean-François Dehecq, Chairman and CEO of sanofi-aventis, set out the guiding principles of his Group's strategy in its Policy of Access to Medicines in the "Southern Countries".

  • FDA issues approvable letter for Ambien CR™ CIV for teh treatment of insomnia

    FDA ISSUES APPROVABLE LETTER FOR AMBIEN CR™ (ZOLPIDEM TARTRATE EXTENDED RELEASE) CIV FOR THE TREATMENT OF INSOMNIA Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for AMBIEN CR™ (zolpidem tartrate extended release) CIV. AMBIEN CR™ is the controlled-release formulation of zolpidem, the world’s

  • Sanofi pasteur awarded $97 million HHS contract to accelerate cell-culture pandemic influenza vaccine development

    Major U.S. public health initiative complements sanofi pasteur’s leadership in global pandemic preparedness Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has been awarded a $97 million contract from the U.S. Health and Human Services Department (HHS) to speed the production process for new cell culture influenza vaccines in the U.S. and the design of a U.S.-based cell-cultu

  • Sanofi-aventis concludes €10 billion in medium-term credit agreements with its banks to refinance the aventis acquisition financing entered into in April 2004

    Sanofi-aventis announced today the simultaneous signature of a medium-term syndicated credit agreement amounting to €8 billion and four bilateral credit facilities amounting to €500 million each. The syndicated credit agreement consists of two revolving credit lines each having a different maturity: • a €5.5 billion five-year tranche with the possibility of extending the maturity up to seven

  • RESCHEDULING OF THE PRE-TRIAL ORDER DATE IN THE UNITED STATES PLAVIX® LITIGATION

    Today sanofi-aventis announced that, at the request of sanofi-aventis, Apotex, and their respective affiliates, the U.S. District Court for the Southern District of New York has approved an extension of the date for submission by the parties of the pre-trial order in its Plavix® patent-infringement litigation with Apotex and Dr. Reddy’s Laboratories. The new date is May 13, 2005. The submission

  • Sanofi-aventis joins the fight against tuberculosis in South Africa

    in partnership with the Nelson Mandela Foundation and the South African Department of Health THE TB FREE PROGRAM for the treatment of tuberculosis sufferers In Johannesburg today, South African Health Minister Dr. Manto Tshabalala-Msimang and sanofi-aventis Chairman and CEO Jean-François Dehecq inaugurated the first training center in support for patients receiving treatment for tuberculosi

  • COURT GRANTS SANOFI-AVENTIS'S REQUEST FOR ORDER OF PROHIBITION IN THE CANADIAN PLAVIX®LITIGATION

    The Canadian Federal Court of Ottawa has granted sanofi-aventis’s application for an order of prohibition against the Minister of Health and Apotex Inc. in relation to Apotex’s 2003 application in Canada for a marketing authorization for a generic version of clopidogrel bisulfate tablets. The Canadian Court rejected Apotex's challenge to the Plavix® patent and held that the asserted claims are nov

  • FDA Advisory Panel Recommends Licensure of sanofi pasteur’s ADACEL™ Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis

    – Vaccine Leader Looks to Introduce First Pertussis Booster for Both Adolescents and Adults in United States Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) voted unanimously to recommend licensure of ADACEL™ (Tetanus Toxoi

  • Sanofi Pasteur seeks to broaden age group for new vaccine, Menactra™, to protect against meningococcal disease

    Submits supplemental license application Sanofi Pasteur, the vaccines business of the sanofi-aventis Group, is seeking U.S. government approval to broaden the age indication for its new meningococcal vaccine Menactra™ (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine). The company has filed a supplemental application with the U.S. Food and Drug Adminis

  • Sanofi-aventis sues Novopharm for patent infringement in Canada

    Sanofi-aventis has learned through the Canadian Ministry of Health website that Novopharm Limited had obtained marketing approval in Canada for a product claiming to be generic enoxaparin. Sanofi-aventis companies Aventis Pharma Inc. and Aventis Pharma S.A. are bringing suit in the Federal Court against Novopharm for patent infringement of Canadian patent 2045433, which covers Lovenox®. Sanofi

  • Clopidogrel improved coronary perfusion and reduced mortality in acute heart attack

    Results from two major clinical trials presented at ACC (PARIS and PRINCETON, NJ, MARCH 9, 2005) – Results of two major clinical trials showed that the antiplatelet agent clopidogrel, given on top of standard therapy, provided significant benefits to patients with acute ST-segment elevation myocardial infarction (STEMI), a certain kind of heart attack. Results of the COMMIT/CCS-2 (ClOpidogrel

  • Sanofi Aventis och Pfizer seek approval to market Exubera® in the United States

    Pfizer Inc. and the sanofi-aventis Group announced today that the United States Food and Drug Administration (FDA) has accepted for filing a new drug application for Exubera® (inhaled human insulin powder). Exubera®, a dry powder form of insulin that is inhaled into the lungs prior to eating, using a specially designed inhalation device, has been studied in more than 3,500 patients, some for o

  • Personalförändring i sanofi-aventis

    Tommy Olin, commercial operations director, med ansvar för sanofi-aventis sälj- och marknadsorganisation har valt att lämna företaget för att gå vidare i en ny karriär utanför organisationen. Han lämnar sanofi-aventis vid månadsskiftet. För ytterligare information kontakta Annette Hedman, tf informationsanvarig, 08-470 18 52 eller 070-289 88 64. Koncernen sanofi-aventis är det tredje störst

  • Sanofi-aventis receives FDA approval for new Eloxatin® formulation

    Sanofi-aventis announced today that he has received marketing approval from the United States Food and Drug Administration for a new formulation of Eloxatin® (oxaliplatin for injection). This new formulation, Eloxatin® INJECTION, is a clear, preservative-free, colorless solution which does not require reconstitution. Eloxatin® INJECTION offers additional benefit and convenience to physicians an

  • Studies demonstrate significant benefit of Eloxatin

    TWO STUDIES DEMONSTRATE SIGNIFICANT BENEFIT OF ELOXATIN– BASED CHEMOTHERAPY COMBINED WITH BEVACIZUMAB IN ADVANCED COLORECTAL CANCER Positive Results of TREE-2 and ECOG 3200 Trials Presented at the 2005 Gastrointestinal Cancers Symposium in Hollywood, Florida Sanofi-aventis (NYSE: SNY) announced today preliminary results of two large prospective trials evaluating the safety and efficacy of E

  • 2004 pro forma combined net sales up 10.0% on a comparable basis

    Sanofi-aventis gains market share from year one After consultation with the stock market authorities in France and the United States, sanofi-aventis has retained August 20 as the date of first consolidation. In 2004, sanofi-aventis generated consolidated net sales of 15,043 million euros compared with 8,048 million euros in 2003. In the fourth quarter of 2004, sanofi-aventis consolidated net

  • Nytt hopp för kvinnor med tidig bröstcancer

    EU-kommissionen har godkänt sanofi-aventis läkemedel Taxotere (docetaxel) för adjuvant behandling, det vill säga direkt efter operation, vid tidig körtelpositiv bröstcancer. Kommissionens beslut baseras på resultatet av en stor långtidsstudie som visar på både en ökad överlevnad och minskad risk för återfall vid behandling med Taxotere. - Detta är framsteg vad gäller bröstcancerbehandling. Resu

  • Sanofi-aventis solidarity day in favour of South East Asia “Sharing in solidarity”

    Sanofi-aventis organizes today, January 25, 2005, a solidarity day in 300 sanofi-aventis sites worldwide to allow Group collaborators to take part in actions undertaken with partner aid agencies in the tsunami-stricken countries. Each employee will be able to share in the movement of solidarity by opting, either to make financial donation to the projects of the villages twinned with his or her

  • Plavix® patent

    Sanofi-aventis has been notified that its patent in the UK issued from its European Patent claiming the active ingredient in its Plavix® product has been challenged by Aircoat, Ltd., a Scottish company, in a Scottish Court. Sanofi-aventis believes Aircoat's arguments to be without merit, and will vigorously defend its patent. Forward-looking statements: This press release contains forward-look

  • Rhodia commenced legal proceedings in US

    Rhodia announced today that it has commenced legal proceedings in the United States of America and Brazil against sanofi-aventis as former owner or operator of the Silver Bow (United States of America) and Cubatao (Brazil) sites to seek to obtain compensation for environmental liabilities related to these two sites. Aventis and Rhodia signed a final settlement agreement on March 27, 2003 pursua

Visa mer
Fyll i din epostadress för att följa Sanofi

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa Sanofi.

Okej